Insulin therapy for non-insulin-dependant diabetes: Minimal or intensive?;L'insulinotherapie du diabete non insulino-dependant: Minimale ou intensifiee

Diabetes and Metabolism

Volumn 23, Issue SUPPL. 3, 1997, Pages 36-43

  Drouin, P ^a  

^a Ctr Hospitalier Univ de Nancy   (France)

Author keywords

Minimal or intensified insulin therapy; Non insulin dependent diabetes

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETIC ANGIOPATHY; FRANCE; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MEDICAL PRACTICE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT INDICATION; CORONARY ARTERY DISEASE; INFUSION PUMP; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; RISK FACTORS;

EID: 0030855869     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Brun JM, Cathelineau G, Charbonnel B et al. Recommandations de l'ALFEDIAM : Mise à l'insuline du diabétique non insulino-dépendant (diabétique de type 2). Diabete Metab, 1995, 21, 291-294.
2. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemic agents : frequency, possible causes, and management. Diabetes Metab Rev, 1994, 10, 31-43.
3. United Kingdom Prospective Diabetes Study (UKPDS) 13. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J, 1995, 310, 83-88.
4. United Kingdom Prospective Diabetes Study (UKPDS) 16. Overview of 6 years'therapy of type II diabetes : a progressive disease. Diabetes, 1995, 44, 1249-1258.
5. Garcia MJ, NcMamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population : sixteen year follow-up study. Diabetes, 1974, 25, 105-111.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
7. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-Yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care, 1993, 16, 434-444.
8. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med, 1991, 151, 1141-1147.
9. Hanis CL, Chu HH, Lawson K et al. Mortality of mexican americans with NIDDM. Diabetes Care, 1993, 16, 82-89.
10. Kannel WR, Mc Gee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease : the Framingham study. Diabetes Care, 1979, 2, 120-126.
11. Fuller JH, Shipley MJ, Rose G. Coronary heart disease risk and impaired glucose tolerance. The Whitehall study. Lancet, 1980, 1, 1373-1376.
12. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1987, 30, 123-131.
13. Laakso M, Rönnemaa T, Lehto S, Puukka P, Kallio V, Pyörälä K. Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations? Diabetologia, 1995, 38, 487-493.
14. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N engl J Med, 1996, 315, 217-225.
15. Welin L, Eriksson H, Larsson B, Ohlson LO, Svärdsudd K, Tibblin G. Hyperinsulinaemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia, 1992, 35, 766-770.
16. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia, 1993, 36, 1175-1184.
17. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes, 1994, 43, 960-967.
18. Gall MA, Borch-Johnscn K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes, 1995, 44, 1303-1309.
19. Hanefeld M, Fischer S, Julius U et al. The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM : the diabetes intervention study, 11-year follow-up. Diabetologia, 1996, 39, 1577-1583.
20. Standl E, Ballctshofer B, Dahl B et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM : the Munich general practitioner project. Diabetologia, 1996, 39, 1540-1545.
21. Fava S, Aquilina O, Azzopardi J, Muscat HA, Fenech FF. The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabetic Med, 1996, 13, 80-83.
22. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. Diabetes Care, 1997, 20, 163-169.
23. Capron L. Mécanismes de l'atteinte macrovasculaire du sujet diabétique. Diabete Metab, 1994, 20, 357-361.
24. Chait A, Bierman EL. Pathogenesis of macrovascular disease in diabetes. In : Kahn CR, Weir G, eds. "Moslin's diabetes mellitus", Philadelphia : Lea & Febiger, 1994, 648-664.
25. Turner RC, Holman RR. Insulin use in NIDDM. Rationale based on pathophysiology of disease. Diabetes Care, 1990, 13, 1011-1020.
26. Genuth S. Insulin use in NIDDM. Diabetes Care, 1990, 13, 1240-1264.
27. Koivisto VA. Insulin therapy in type II diabetes. Diabetes Care, 1993, 16 (Suppl 3), 29-39.
28. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Application, benefits and risks. Diabetes Rev, 1995, 3, 308-334.
29. Taskinen MR, Sane T, Helve E, Karonen SL, Nikkilä EA†, Yki-Järvinen H. Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes, 1989, 38, 580-588.
30. Yki-Järvinen H, Kauppila M, Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N engl J Med, 1992, 327, 1426-1433.
31. Groop LC, Groop PH, Stenman S. Combined insulin-sulfonylurea therapy in treatment of NIDDM. Diabetes Care, 1990, 13 (Suppl 3), 47-52.
32. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients ? Diabetes Care, 1992, 15, 953-959.
33. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes, 1995, 44, 165-172.
34. Floyd JC, Funnell MM, Kazi I, Templeton C. Feasibility of adjustment of insulin dose by insulin-requiring type II diabetic patients. Diabetes Care, 1990, 13, 386-392.
35. Lindström TH, Arnqvist HJ, Von Schenck HH, Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM. Diabetes Care, 1992, 15, 27-34.
36. Kudlacek S, Schernthaner G. The effect of insulin treatment on HbAlc, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res, 1992, 24, 478-483.
37. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Diabetes Care, 1993, 16, 21-31.
38. Clauson P, Karlander S, Steen L, Efendic S. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure : a 1 -year follow-up. Diabetic Med., 1996, 13, 471-477.
39. Birkcland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM : a rapid progressive disease Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia, 1996, 39, 1629-1633.
40. Abraira C, Colwell JA, Nuttall FQ et al. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Diabetes Care, 1995, 18, 1113-1123.
41. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes, 1985, 34, 222-234.
42. Glaser B, Leibovich G, Nesher R, Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol, 1988, 118, 365.
43. Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley C, Ward JD. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care, 1991, 14, 738-744.
44. Duckworth WC, Saudek CD, Henry RR. Perspectives in diabetes. Why intraperitoneal delivery of insulin with implantable pumps in NIDDM ? Diabetes, 1992, 41, 657-661.
45. Groop L, Widen E, Franssila-Kallunki A, Ekstrand A et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1989, 32, 599-605.
46. Barnett AH, Bowen Jones D, Burden AC et al. Multicentre study to assess quality of life and glycaemic control of type 2 diabetic patients treated with insulin compared with oral hyoglycaemic agents. Pract Diabetes Int, 1996, 13, 179-183.
47. Expert Committee of the Canadien Diabetes Advisory Board. Clinical practice guidelines for the treatment of diabetes mellitus. Can Med Assoc I, 1992, 147, 697-712.
48. Wolffenbuttel BHR, Sels JPJE, Rondas-Colbers GJWM, Menheere PPCA, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care, 1996, 19, 1326-1332.
49. Malmberg K, Rydén L, Effendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study) : effects on mortality at 1 year. J Am Coll Cardiol, 1995, 26, 57-65.
50. Malmberg K for the DIGAMI Study group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J, 1997, 314, 1512-1515.